Toll‐like receptor 9 binds single‐stranded CpG‐DNA in a sequence‐ and pH‐dependent manner

• Published in: European Journal of Immunology 2004-09, Vol.34 (9), p.2541-2550
• Main Authors: Rutz, Mark, Metzger, Jochen, Gellert, Tanja, Luppa, Peter, Lipford, Grayson B., Wagner, Hermann, Bauer, Stefan
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Binding Sites; Cell Line; Chloroquine; Chloroquine - pharmacology; CpG Islands; CpG‐DNA; DNA, Single-Stranded - metabolism; Humans; Hydrogen-Ion Concentration; MBD domain; Membrane Glycoproteins - chemistry; Membrane Glycoproteins - metabolism; Molecular Sequence Data; Quinacrine - pharmacology; Receptors, Cell Surface - chemistry; Receptors, Cell Surface - metabolism; Surface plasmon resonance (biacore); TLR9; Toll-Like Receptor 2; Toll-Like Receptor 9; Toll-Like Receptors
• ISSN: 0014-2980; 1521-4141; 1365-2567
• DOI: 10.1002/eji.200425218

Toll‐like receptors (TLR) recognize bacterial and viral components, but direct interaction of receptor and ligand is unclear. Here, we demonstrate that TLR9 binds directly and sequence‐specifically to single‐stranded unmethylated CpG‐DNA containing a phosphodiester backbone. TLR9‐CpG‐DNA interaction occurs at the acidic pH (6.5–5.0) found in endosomes and lysosomes. By sequence comparison we identified a potential CpG‐DNA binding domain homologous to that described for methyl‐CpG‐DNA binding proteins. Amino acid substitutions in this region abrogated CpG‐DNA binding and led to loss of NF‐κB activation. Furthermore, chloroquine and quinacrine, therapeutic agents for autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, directly blocked TLR9‐CpG‐DNA interaction but not TLR2‐Pam3Cys binding. Our results demonstrate direct binding of TLR9 to CpG‐DNA and suggest that the therapeutic activity of chloroquine and quinacrine in autoimmune diseases may be due to its activity as a TLR9 antagonist and inhibitor of endosomal acidification.